In vitro effects of tacrolimus on human cytochrome P450. - NCBI
Tacrolimus, a potent immunosuppressive drug, is known to be metabolized predominantly in the liver by cytochrome P450 3A CYP3A. Cytochrome P-450 Enzyme System/metabolism; Dose-Response Relationship, Drug; Drug Interactions. Jun 1, 2010. CYP3A5; tacrolimus; diltiazem; drug–drug interaction; prospective study. Diltiazem is a potent mechanism-based inhibitor of CYP3A. CYP3A or P-glycoprotein. CYP activity in the liver also influences tacrolimus concentrations. As a result, several drugs that are frequently being used in trans-.
Effects of diltiazem on pharmacokinetics of tacrolimus in. - Nature
Apr 27, 2017. Metronidazole and Tacrolimus Interaction in a Kidney Transplant. Tacrolimus is metabolized primarily in the liver by CYP3A enzymes and. In clinical studies, CYP3A/P-glycoprotein inhibitors and inducers primarily affect oral bioavailability of tacrolimus rather than its clearance, indicating a key role of. Jul 20, 2016. Toxicity can occur from overdosing or from drug-drug interactions with. Different CYP3A alleles seem to be directly related to tacrolimus dose.
Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and.
Dec 28, 2011. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically with various drugs. BACKGROUND Tacrolimus is an immunosuppressive drug that is a. All other medications, including those known to interact with CYP3A and/or P-gp, were.